= Additional active ingredients
PRESENTATION AND DOSSAGE
TABS: 30 x 12.5 mg
TABS: 30 x 50 mg
TABS: 30 x 100 mg
Hypertension.Heart failure: For the treatment of heart failure (NYHA II and III) usually in addition to diuretics and/or digitalis if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: To delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: To reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit on the primary deposit endpoint was largely driven by reduction in the risk of stroke.
Pregnancy and lactation. Hypersensitivity.
Past or present allergies, impaired renal or hepatic function, increased fluid loss. impaired function of the heart valves. Patient should not drink wine or other alcoholic beverages. See literature/package insert.
Some patients, especially patients with type 2 diabetes accompanied by protein in the urine, may develop increased blood potassium levels. See literature/package insert.
Potassium sparing agents, potassium supplements or salt substitutes containing potassium, rifampicin, fluconazole, lithium, NSAIDs, COX-2 inhibitors, high doses of diuretics.
MANUFACTURER & DISTRIBUTER:
Manufacturer: Dexcel Pharma Technologies
License Holder: Dexcel Ltd., a Dexxon company